Cookie policy: This site uses cookies (small files stored on your computer) to simplify and improve your experience of this website. Cookies are small text files stored on the device you are using to access this website. For more information please take a look at our terms and conditions. Some parts of the site may not work properly if you choose not to accept cookies.


Subscribe or Register

Existing user? Login

Product update

Side effects associated with estrogen-progestogen treatment

The summary of product characteristics for Tridestra (estradiol valerate, medroxyprogesterone acetate; Orion) now states that estrogen-progestogen treatment is associated with myocardial infarction, gall bladder disease, chloasma, erythema multiforme, pancreatitis and probable dementia over the age of 65 years. Hereditary angiodema has been added to the list of conditions that require supervision with Tridestra treatment.

Citation: The Pharmaceutical Journal DOI: 10.1211/PJ.2015.20069148

Have your say

For commenting, please login or register as a user and agree to our Community Guidelines. You will be re-directed back to this page where you will have the ability to comment.

Recommended from Pharmaceutical Press

Search an extensive range of the world’s most trusted resources

Powered by MedicinesComplete
  • Print
  • Share
  • Comment
  • Save
  • Print Friendly Version of this pagePrint Get a PDF version of this webpagePDF

Newsletter Sign-up

Want to keep up with the latest news, comment and CPD articles in pharmacy and science? Subscribe to our free alerts.